发明名称 |
IL-1 binding proteins |
摘要 |
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. |
申请公布号 |
US9447183(B2) |
申请公布日期 |
2016.09.20 |
申请号 |
US201314107988 |
申请日期 |
2013.12.16 |
申请人 |
AbbVie Inc. |
发明人 |
Wu Chengbin;Ambrosi Dominic J.;Hsieh Chung-ming;Ghayur Tariq |
分类号 |
C12P21/08;A61K38/00;C07K14/545;C07K16/24;A61K47/48;A61K45/06;G01N33/68;A61K39/395;A61K9/00 |
主分类号 |
C12P21/08 |
代理机构 |
Lathrop & Gage LLP |
代理人 |
Lathrop & Gage LLP ;Velema, Esq. James H. |
主权项 |
1. A method for reducing human IL-1 activity in a human subject in need thereof, comprising administering to the human subject a binding protein, wherein the binding protein comprises first and second polypeptide chains, wherein said first polypeptide chain comprises a first VD1-(X1)n-VD2-C-(X2)n, wherein:
VD1 is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 is an Fc region; and n is independently 0 or 1; and wherein said second polypeptide chain comprises a second VD1-(X1)n-VD2-C-(X2)n, wherein: VD1 is a first light chain variable domain; VD2 is a second light chain variable domain; C is a light chain constant domain; X1 is a linker with the proviso that it is not CH1; X2 does not comprise an Fc region; and n is independently 0 or 1; wherein, in said first polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO: 204; and VD2 comprises the amino acid sequence of SEQ ID NO: 213; wherein, in said second polypeptide chain, VD1 comprises the amino acid sequence of SEQ ID NO: 238; and VD2 comprises the amino acid sequence of SEQ ID NO: 216; and wherein the binding protein binds human IL-1β and human IL-la, such that the human IL-1 activity in the human subject is reduced. |
地址 |
North Chicago IL US |